CT1812 exhibits weak influence on CYP probe drug plasma concentrations

CT1812 causes weak inhibition of CYP2D6 and weak induction of CYP3A4/5

CT1812 is a sigma-2/PGRMC1 antagonist that displaces receptor-bound Aβ oligomers, clears them into CSF and improves memory

CT1812 displaces Aβ oligomer bound to synapses on neurons and clears them into CSF

CONCLUSIONS

1. In the transgenic animal performance (Aβ oligomers), the treatment presented in this study was substantially lower than the baseline performance (CT1812 vs. vehicle), which indicates that CT1812 has a negative effect on the performance of the transgenic animals.

2. In the Morris water maze task (Aβ oligomers), the CT1812 group showed a significant improvement in the latency to find the platform compared to the vehicle group, which indicates that CT1812 has a positive effect on the spatial memory of the transgenic animals.

Alzheimer’s Association International Conference, London, UK 2017